• Publications
  • Influence
Standardization of food challenges in patients with immediate reactions to foods – position paper from the European Academy of Allergology and Clinical Immunology
At present, the double blind placebo controlled foodchallenge(DBPCFC)representstheonlywaytoestablishorruleoutanadversereactiontoafoodinolderchildrenand adults, whereas an open challenge controlledExpand
  • 621
  • 26
  • PDF
Apple allergy across Europe: how allergen sensitization profiles determine the clinical expression of allergies to plant foods.
BACKGROUND Allergy to a plant food can either result from direct sensitization to that food or from primary sensitization to pollen, latex, or another food. OBJECTIVE We sought to investigate theExpand
  • 300
  • 14
Ara h 8, a Bet v 1-homologous allergen from peanut, is a major allergen in patients with combined birch pollen and peanut allergy.
BACKGROUND We recently described patients with soybean allergy mainly mediated by cross-reactivity to birch pollen allergens. A majority of those patients were reported to have peanut allergy. Expand
  • 272
  • 14
SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis
Background SDZ ASM 981 is a selective inhibitor of the production of pro‐inflammatory cytokines from T cells and mast cells in vitro. It is the first ascomycin macrolactam derivative underExpand
  • 212
  • 9
Relevance of Ara h1, Ara h2 and Ara h3 in peanut‐allergic patients, as determined by immunoglobulin E Western blotting, basophil–histamine release and intracutaneous testing: Ara h2 is the most
Background A number of allergenic proteins in peanut has been described and the relative importance of these allergens is yet to be determined.
  • 232
  • 8
The distribution of individual threshold doses eliciting allergic reactions in a population with peanut allergy.
BACKGROUND Hidden peanut in consumer products can endanger patients with peanut allergy. Individual threshold doses for eliciting allergic reactions need to be elucidated to assess the risks forExpand
  • 193
  • 7
Effect of Varying Doses of Epicutaneous Immunotherapy vs Placebo on Reaction to Peanut Protein Exposure Among Patients With Peanut Sensitivity: A Randomized Clinical Trial
Importance Epicutaneous immunotherapy may have potential for treating peanut allergy but has been assessed only in preclinical and early human trials. Objective To determine the optimal dose, adverseExpand
  • 94
  • 7
Silencing the major apple allergen Mal d 1 by using the RNA interference approach.
BACKGROUND Apple allergy is dominated by IgE antibodies against Mal d 1 in areas where birch pollen is endemic. Apples with significantly decreased levels of Mal d 1 would allow most patients inExpand
  • 149
  • 7
Purification and immunoglobulin E‐binding properties of peanut allergen Ara h 6: evidence for cross‐reactivity with Ara h 2
Background IgE‐binding peanut proteins smaller than 15 kDa were previously identified as potential allergens in the majority of our peanut allergic population.
  • 112
  • 5
How much is too much? Threshold dose distributions for 5 food allergens.
BACKGROUND Precautionary labeling is used to warn consumers of the presence of unintended allergens, but the lack of agreed allergen thresholds can result in confusion and risk taking by patientsExpand
  • 102
  • 5